<DOC>
	<DOCNO>NCT00093405</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , 17-N-allylamino-17-demethoxygeldanamycin , work different way stop tumor cell divide stop grow die . 17-N-allylamino-17-demethoxygeldanamycin may also stop growth tumor cell block enzymes necessary growth . PURPOSE : This phase II trial study well 17-N-allylamino-17-demethoxygeldanamycin work treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) patient metastatic papillary clear cell renal cell carcinoma . Secondary - Determine safety drug patient . - Correlate tumor c-met expression response patient treated drug . OUTLINE : This open-label study . Patients stratify accord histology ( papillary v clear cell ) . Patients receive 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) IV 60-90 minute day 1 , 4 , 8 , 11 . Treatment repeat every 21 day 1 year absence disease progression unacceptable toxicity . Patients follow 3 week every 3 month thereafter . PROJECTED ACCRUAL : A total 24-74 patient ( 12-37 per stratum ) accrue study within 6-20 month ( clear cell stratum ) 2-5 year ( papillary stratum ) .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Papillary OR clear cell histology If histology present , clear cell papillary must predominant Metastatic disease Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No brain metastasis unless previously treat radiotherapy surgery AND asymptomatic active brain metastasis detectable CT scan MRI ≥ 6 month PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST ALT ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Renal Creatinine ≤ 2.0 time ULN Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No severe valvular disease Pulmonary No severe debilitate pulmonary disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No allergy egg egg product No history allergic reaction attribute compound similar chemical biological composition 17Nallylamino17demethoxygeldanamycin ( 17AAG ) No active ongoing infection require IV antibiotic No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy No 1 prior cytokinebased regimen No concurrent biologic therapy Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy No concurrent radiotherapy Surgery More 4 week since prior major surgery Other Recovered prior therapy No 1 prior noncytokinebased regimen No prior systemic treatment regimens No concurrent cytotoxic therapy No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
</DOC>